Several other equities analysts have also recently issued reports on RGNX. Raymond James initiated coverage on Adverum Biotechnologies in a research report on Thursday, June 13th. They issued a market perform rating on the stock. ValuEngine cut Yext from a strong-buy rating to a buy rating in a research report on Friday, May 10th. TheStreet cut Trade Desk from a b- rating to a c- rating in a research report on Thursday, May 9th. Chardan Capital restated a buy rating and issued a $150.00 price target (up previously from $145.00) on shares of Regenxbio in a research report on Tuesday, June 18th. Finally, Zacks Investment Research cut Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, May 11th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $81.53.
Regenxbio stock opened at $47.48 on Thursday. Regenxbio has a fifty-two week low of $38.56 and a fifty-two week high of $83.45. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $48.19.
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.04). Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. The firm had revenue of $0.88 million during the quarter. On average, equities research analysts expect that Regenxbio will post -2.46 EPS for the current year.
In other Regenxbio news, insider Olivier Danos sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $52.66, for a total transaction of $105,320.00. Following the transaction, the insider now owns 8,500 shares in the company, valued at approximately $447,610. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $53.23, for a total value of $266,150.00. Following the transaction, the senior vice president now owns 6,547 shares in the company, valued at approximately $348,496.81. The disclosure for this sale can be found here. Insiders sold a total of 75,000 shares of company stock worth $3,725,970 in the last 90 days. 13.80% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Redmile Group LLC lifted its stake in shares of Regenxbio by 4.8% during the 1st quarter. Redmile Group LLC now owns 1,420,342 shares of the biotechnology company’s stock worth $81,400,000 after purchasing an additional 65,600 shares during the period. SG3 Management LLC purchased a new position in shares of Regenxbio during the 1st quarter worth $115,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Regenxbio during the 1st quarter worth $643,000. Botty Investors LLC lifted its stake in shares of Regenxbio by 8.1% during the 1st quarter. Botty Investors LLC now owns 240,737 shares of the biotechnology company’s stock worth $13,797,000 after purchasing an additional 18,090 shares during the period. Finally, GAM Holding AG lifted its stake in shares of Regenxbio by 74.6% during the 1st quarter. GAM Holding AG now owns 111,575 shares of the biotechnology company’s stock worth $6,394,000 after purchasing an additional 47,675 shares during the period. Institutional investors own 81.48% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: How Do Mutual Funds Work?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.